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Abstract
Background: Leukocyte telomere length (LTL) is an emerging marker of biological age. Chronic inflammatory activity is
commonly proposed as a promoter of biological aging in general, and of leukocyte telomere shortening in particular. In
addition, senescent cells with critically short telomeres produce pro-inflammatory factors. However, in spite of the proposed
causal links between inflammatory activity and LTL, there is little clinical evidence in support of their covariation and
interaction.
Methodology/Principal Findings: To address this issue, we examined if individuals with high levels of the systemic
inflammatory markers interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and C-reactive protein (CRP) had increased odds
for short LTL. Our sample included 1,962 high-functioning adults who participated in the Health, Aging and Body
Composition Study (age range: 70–79 years). Logistic regression analyses indicated that individuals with high levels of either
IL-6 or TNF-a had significantly higher odds for short LTL. Furthermore, individuals with high levels of both IL-6 and TNF-a
had significantly higher odds for short LTL compared with those who had neither high (OR=0.52, CI=0.37–0.72), only IL-6
high (OR=0.57, CI=0.39–0.83) or only TNF-a high (OR=0.67, CI=0.46–0.99), adjusting for a wide variety of established risk
factors and potential confounds. In contrast, CRP was not associated with LTL.
Conclusions/Significance: Results suggest that cumulative inflammatory load, as indexed by the combination of high levels
of IL-6 and TNF-a, is associated with increased odds for short LTL. In contrast, high levels of CRP were not accompanied by
short LTL in this cohort of older adults. These data provide the first large-scale demonstration of links between inflammatory
markers and LTL in an older population.
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Introduction
Telomeres, the DNA-protein complexes that cap the ends of
chromosomes and protect against genomic instability, contain
variable-length tracts of telomeric DNA. Leukocyte telomere
length (LTL) is increasingly recognized as an index of biological
age that predicts incidence of age-related diseases [1,2], as well as
all-cause and disease-specific mortality in diverse cohorts of older
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19687adults [1,3,4,5,6]. In fact, older adults with below average LTL
have more than threefold increased risk for early mortality [4,6].
Long LTL is also a predictor of years of healthy living, an outcome
that integrates self-perceived functional status and duration of
survival [7]. Importantly, telomere shortening is not just an index,
but also a potential mechanism underlying some aspects of
biological aging because short telomere length can lead to
cessation of mitosis with consequent loss of ability for cell
replenishment and, in some cellular settings, genomic instability,
end-to-end chromosome fusion, and apoptosis as well as harmful
DNA damage signaling and mitochondrial dysfunction
[8,9,10,11]. Notwithstanding the utility of LTL in predicting
mortality and longevity, there is little clinical evidence regarding
modifiable factors associated with and potentially driving leuko-
cyte telomere shortening.
Inflammatory activity is frequently proposed as a contribu-
tor to biological aging in general, and leukocyte telomere
shortening in particular [5,12,13,14]. Accumulating evidence
suggests a causal role for inflammation in the pathogenesis of
multiple age-related diseases including cancer, atherosclerosis,
autoimmune disorders, diabetes, and neurodegenerative diseases
[15,16,17,18,19,20,21]. Elevated inflammatory activity could
accelerate leukocyte telomere shortening by promoting cell
turnover and replicative senescence [22], and by inducing the
release of reactive oxygen species that damage telomeric DNA via
oxidative stress [23]. One complication is that inflammatory
cytokines including tumor necrosis factor-a (TNF-a) can both
inhibit and promote activity of telomerase [24,25,26], the cellular
enzyme primarily responsible for lengthening telomeres [27]. On
the other hand, in vitro research on various cell types, but not
including normal leukocytes, indicates that an accumulation of
senescent cells with critically short LTL may produce pro-
inflammatory factors [28,29], hich could in turn contribute to an
increased inflammatory load.
Observations of short LTL in small samples of patients with
inflammatory diseases including hepatitis C, liver cirrhosis, chronic
kidney disease and chronic obstructive pulmonary disease provide
preliminary support for the proposal that inflammation accelerates
leukocyte telomere shortening [5,14,30,31]. Specifically, in these
studies, patients with inflammatory disorders exhibited shorter
LTL cross-sectionally compared with healthy individuals [31,32],
and shorter telomeres in cells proximal to disease-related
inflammatory activity [14,30]. Additionally, elevations in disease-
specific and systemic inflammatory markers have been associated
with short LTL in patients [5]. Although there are plausible
pathways by which inflammation could accelerate telomere
shortening even in adults without chronic disease, little is known
about in vivo relationships between markers of inflammation and
LTL in healthy older adults.
In the present study, we examined if elevated inflammatory
activity, indexed by high levels of the systemic inflammatory
cytokines interleukin-6 (IL-6) and TNF-a and the acute phase
protein C-reactive protein (CRP), is associated with increased
risk for short LTL in the ‘Health, Aging and Body Composition’
(Health ABC) cohort, a large sample of well-functioning men
and women aged 70–79 years. Our sample included 1,962
Health ABC participants who had complete data available for
our primary analyses. We hypothesized that participants with
high levels of IL-6 and/or TNF-a and/or CRP would be more
likely than participants with lower levels of these inflammatory
markers to have short LTL, and that the combination of high
IL-6, high TNF-a and high CRP, as an index of a high
cumulative inflammatory load, would confer the greatest odds
for short LTL.
Results
In spite of the restricted age range of the sample, age was
significantly associated with shorter LTL (r=2.07, p=.002) and
higher levels of TNF-a (r=.07, p=.003). However, age was
negatively associated with levels of CRP (r=2.07, p=.001) and
was not associated with levels of IL-6 (r=.03, p=.19). Inflamma-
tory markers were significantly and positively associated with one
another. However, while the effect size for the relationship
between IL-6 and CRP was medium to large (r=.47, p,.001),
relationships between IL-6 and TNF-a (r=.27, p,.001) as well as
between TNF-a and CRP (r=.11, p,.001) had smaller effect
sizes. Table 1 summarizes the baseline characteristics of the study
population stratified by LTL tertile. As predicted, participants in
the bottom tertile for LTL had the highest level of IL-6 and TNF-
a, but there were no differences between groups in levels of CRP.
Inflammatory Activity and LTL
In our primary analytic model, we found that the odds of having
short LTL (i.e., LTL in the bottom tertile or #4260 bp) were
significantly higher for those participants who had high (i.e., top
tertile) levels of either IL-6 ($2.39 pg/mL), TNF-a ($3.72 pg/
mL) or CRP ($2.51 mg/L). In these analyses, the results of which
are summarized in Table 2, groups were not mutually exclusive,
such that the same individual could be represented in multiple
groups if he or she had high levels of IL-6, TNF-a and CRP.
Adjusting for a wide range of potential confounds and covariates,
the odds for short LTL were significantly higher in those who had
either IL-6 levels in the top tertile (OR=1.3, 95% CI=1.1–1.7) or
TNF-a levels in the top tertile (OR=1.5, 95% CI=1.2–1.9). The
highest odds for short LTL were observed in those participants
who had high levels of both IL-6 and TNF-a (OR=1.8, CI=1.3–
2.4). In contrast, the addition of high levels of CRP did not confer
increased odds for short LTL, as indexed by the lack of association
between CRP and LTL (OR=1.1, 95% CI=08–1.4), and by the
roughly equal odds of having short LTL for those who had high
levels of CRP in addition to high levels of IL-6 and TNF-a
(OR=1.7, CI=1.1–2.6).
We additionally ran the same models using the established high-
risk clinical cutoff (.3 mg/L) for CRP [33]. While individuals
who had CRP above this clinical cutoff had marginally higher
odds for short LTL, this was not significant in any of the models,
including when we only adjusted for telomere batch (OR=1.3,
CI=1.0–1.7). Thus, individuals with CRP in either the top tertile
in the sample or above the recognized clinical cutoff did not
appear to have significantly increased odds for short LTL.
To further examine the observed associations of IL-6 and TNF-
a with short LTL and to compare mutually exclusive groups
instead of potentially overlapping groups, we excluded CRP from
our model and compared the odds for short LTL among four
mutually exclusive groups of participants: those with both high IL-
6 and high TNF-a; only high IL-6; only high TNF-a; and neither
high IL-6 nor high TNF-a. These analyses were conducted while
statistically controlling for established risk factors and potential
confounds and with both high IL-6 and high TNF-a as our
reference group. Results indicated that the combination of both
high IL-6 and high TNF-a levels was associated with roughly
double the odds for short LTL compared with having neither high
IL-6 nor high TNF-a (OR=0.52, CI=0.37–0.72). Furthermore,
the combination of high IL-6 and high TNF-a was associated with
significantly higher odds for short LTL compared with having only
IL-6 high (OR=0.57, CI=0.39–0.83) or only TNF-a high
(OR=0.67, CI=0.46–0.99). Finally, mean LTL adjusted for site,
age, gender, and race was 201 base pairs shorter in participants
Inflammation and Telomere Length
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SE=68.07) compared with that of participants who did not have
high levels of both of these (M=4902.21 bp, SE=28.20), and this
difference in absolute LTL was significant, F(1,1937)=7.35,
p=.007.
Discussion
Short LTL, a potential index of biological age, is associated with
increased risk for age-related diseases as well as early all-cause and
disease-specific mortality [3,4,5,6]. The present research study is
to date the largest to demonstrate an association between elevated
inflammatory activity and short LTL. Moreover, the present study
is the first to indicate that the combination of high IL-6 and TNF-
a is associated with increased odds for short LTL, over and above
the odds associated with having high levels of only one of these
markers. Of note, having high levels of both IL-6 and TNF-a
conferred almost twice the odds of being in the bottom tertile for
LTL compared with having lower levels of both markers. In
contrast, having high levels of CRP, as indexed by CRP levels
either in the top tertile for the sample or above the established
clinical cutoff, was not associated with increased odds for short
LTL. Importantly, all of our results held when controlling for the
contribution of numerous established risk factors for short LTL
and potential confounds. Together with the observed causal
relationships between inflammatory activity and LTL in animal
Table 1. Sample characteristics by leukocyte telomere length (LTL) tertile.
LTL Tertile
Short Middle Long p value
LTL (base pairs) #4260 4261–5280 .5280
Age (years), M (SD) 74.0 (2.8) 73.5 (2.9) 73.4 (2.9) ,.01**
Race (Black), n (%) 239 (36.5) 274 (41.8) 271 (41.6) .09
Sex (female), n (%) 255 (39.0) 330 (50.3) 398 (61.0) ,.01**
Site (Memphis), n (%) 324 (49.5) 367 (56.0) 293 (44.9) ,.01**
Body mass index (kg/m
2) 27.6 (4.8) 27.4 (4.9) 27.3 (4.7) .59
Smoking status, n (%)
Current 72 (11.0) 73 (11.1) 66 (10.1)
Former 319 (48.8) 305 (46.5) 270 (41.4)
Never 263 (40.2) 278 (42.4) 316 (48.5) .04*
Sleep (hours/night) 6.9 (1.3) 6.9 (1.4) 6.8 (1.3) .79
Alcohol (drinks/week), n (%)
0 303 (46.3) 333 (50.7) 328 (50.3)
,1 142 (21.7) 144 (22.0) 129 (19.8)
1–7 160 (24.5) 135 (20.6) 142 (21.8)
.7 49 (7.5) 44 (6.7) 53 (8.1) .46
Exercise (kcal/kg/week) 85.9 (73.5) 85.7 (73.1) 82.6 (64.0) .93
Chronic condition, n (%) 444 (67.9) 448 (68.2) 464 (71.2) .38
Recent infection, n (%) 43 (6.6) 46 (7.0) 52 (8.0) .61
Anti-inflammatory medications, n (%) 344 (52.6) 356 (54.3) 332 (50.9) .48
Statins, n (%) 89 (13.6) 79 (12.0) 97 (14.9) .32
Income, n (%)
,10 k 68 (10.4) 86 (13.1) 88 (13.5)
10 k–25 k 262 (40.0) 272 (41.5) 242 (37.1)
25 k–50 k 217 (33.2) 205 (31.3) 218 (33.4)
.50 k 107 (16.4) 93 (14.2) 104 (16.0) .38
Education, n (%)
,HS 156 (23.9) 166 (25.3) 123 (18.9)
HS 191 (29.2) 184 (28.1) 186 (28.4)
.HS 307 (46.9) 306 (46.7) 343 (52.6) .05*
Interleukin-6: Mdn (IQR) 1.9 (1.3–3.0) 1.8 (1.3–2.8) 1.7 (1.2–4.5) .05*
Tumor necrosis factor-a: Mdn (IQR) 3.4 (2.7–4.4) 3.2 (2.5–4.1) 3.0 (2.3–3.8) ,.01**
C-reactive protein: Mdn (IQR) 1.6 (1.0–3.0) 1.6 (0.9–3.0) 1.74 (1.0–3.3) .17
Notes. HS=high school; IQR=interquartile range; LTL=leukocyte telomere length; M=mean; Mdn=Median; n=number of participants; SD=standard deviation;
p-values for comparisons of means were calculated using one-way ANCOVA tests for continuous variables, and chi-squared tests for categorical variables. One-way
ANCOVAs were calculated using log-transformed values because variances were not equal between groups. However, reported means and medians are based on raw
data.
doi:10.1371/journal.pone.0019687.t001
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adjunct anti-inflammatory therapies could potentially prevent
accelerated leukocyte telomere shortening or protect against the
negative effects of short LTL in older adults.
We included IL-6, TNF-a and CRP as three separate measures
of systemic inflammatory activity in our study. Although all of
these inflammatory markers were significantly correlated with
one another, relationships between them were not strong
(r’s#.47). IL-6 and CRP were the most strongly associated of
the inflammatory markers, sharing 22% of variance. Given that
IL-6 is a major inducer of CRP production by hepatocytes
[34,35], the larger effect size for the relationship between these
markers is not unexpected. However, high levels of IL-6, but not
high levels of CRP, were associated with increased odds of short
LTL in the sample. There is evidence that IL-6 is necessary but
not sufficient to induce CRP synthesis [36], and also evidence
that human coronary artery smooth muscle cells may produce
CRP and that IL-6 is not a necessary inducer of CRP synthesis by
these cells [37]. Thus, although IL-6 is an inducer of CRP and
their concentrations are correlated, the physiological actions of
IL-6 and CRP are not expected to be identical. The present
findings, which need to be further investigated, suggest that in the
case of LTL, these two factors do not have the same effects.
Notably with regard to our overall findings, IL-6 and TNF-a
shared only 7% of variance, supporting the formulation that
circulating levels of these cytokines reflect different aspects of the
inflammatory response. Thus, while each of these cytokines may
contribute to leukocyte telomere shortening by promoting cell
turnover and replicative senescence, inducing oxidative stress,
and regulating telomerase activity [22,23,24,25,26], chronic
exposure to the cumulative load of both high IL-6 and high
TNF-a may have the greatest impact on the rate of leukocyte
telomere shortening.
Equally plausible, however, is the emerging hypothesis that
participants with short LTL in our study had the greatest
proportion of accumulated senescent bodily cells overall, including
fibroblasts and epithelial cells, which could plausibly contribute to
the observed higher levels of IL-6 and TNF-a in this group
[28,38]. Given that TNF-a and IL-6 may inhibit programmed cell
death in specific cell types [39,40], high levels of these cytokines
could even contribute to the maintenance of senescent cells in the
system and hence the continued production of pro-inflammatory
factors. However, the cross-sectional design of our study precludes
drawing conclusions about the causal direction in the relationship
between inflammatory activity and LTL.
In previous research, the cumulative load of high IL-6, high
TNF-a and high CRP was found to confer the greatest risk for
cardiovascular events in the Health ABC cohort [7]. However,
CRP did not likewise contribute to the predictive value of the
inflammatory markers with regard to LTL. Our finding of no
association between CRP and LTL is in line with a previous
finding of no associations between CRP and LTL in post-
menopausal women, and in ‘Cardiovascular Health Study’
participants who were older than 73 years [7]. However, this
finding does not support our hypothesis that higher levels of all
measures of inflammatory activity would be associated with
shorter LTL. Previous research has demonstrated that although
CRP is reliably associated with cardiovascular disease (CVD)
outcomes, CRP does not appear to be causally involved in the
development of CVD [41]. Furthermore, CRP is less predictive of
CVD in older compared with younger adults [42,43] and CRP
levels were not predictive of cardiovascular events in a sample of
high-risk Japanese adults in whom IL-6 was an independent
predictor of such events [44]. However, it is possible that CRP
would be associated with LTL in older populations with other
diseases, such as inflammatory diseases characterized by very high
levels of CRP. Our findings in relation to CRP may have
particular relevance in clinical settings where CRP is the most
commonly used index of inflammatory activity because they
suggest that pro-inflammatory cytokine concentrations may serve
as complementary indices of inflammation.
The present findings must be interpreted in the context of
several limitations. First, the cross-sectional design of the present
study precludes causal interpretations. Second, the narrow age
range of our sample of older adults (70–79 years) is both a strength
and weakness of our study. While this narrow age range allows us
to maximize power to detect associations between inflammatory
activity and LTL without many of the confounding factors
associated with a sample of wider age range (e.g., cohort effects,
hormonal effects), the findings of the present study may not be
generalizable to other stages of the lifespan. Moreover, anti-
inflammatory medications were common in our sample of older
adults. Given the wide range of medications that have anti-
inflammatory effects and the variability in dosage across
individuals, our statistical control for anti-inflammatory medica-
tions is likely to be insufficient but is the best option currently
Table 2. Systemic inflammatory markers as predictors of short leukocyte telomere length.
Unadjusted Adjusted for age, gender and race Adjusted for all covariates
OR (95% CI) OR (95% CI) OR (95% CI)
IL-6 1.3 (1.0–1.6)* 1.3 (1.0–1.6)* 1.3 (1.0–1.7)*
TNF-a 1.6 (1.3–2.1)** 1.5 (1.2–1.91)** 1.5 (1.2–1.9)**
CRP 0.9 (0.7–1.1) 1.1 (0.86–1.4) 1.1 (0.8–1.4)
IL-6+TNF-a 1.9 (1.4–2.6)** 1.7 (1.3–2.4)** 1.8 (1.3–2.4)**
IL-6+CRP 1.1 (0.9–1.5) 1.3 (0.9–1.7) 1.3 (0.9–1.7)
TNF-a+CRP 1.6 (1.2–2.2)** 1.7 (1.2–2.4)** 1.7 (1.2–2.4)**
IL-6+TNF-a+CRP 1.7 (1.2–2.5)** 1.7 (1.1–2.5)** 1.7 (1.1–2.6)**
Notes.
*indicates p,.05 and
**indicates p,.01;
OR refers to odds ratio based on logistic regression; 95% CI is the 95% confidence interval; IL-6=Interleukin-6; TNF-a=Tumor necrosis factor-a; CRP=C-reactive protein.
doi:10.1371/journal.pone.0019687.t002
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different methods used to assay LTL and the Q-PCR method has
been subject to criticism [45,46]. However, strong associations
between LTL as assessed by the Southern blot method and Q-
PCR method have been documented [47], and the coefficient of
variation of the LTL assay for this study was low at 4%. In
addition, some findings related to LTL in Health ABC have been
replicated in a cohort who had LTL measured with the traditional
Southern blot technique [48]. Finally, it should be noted that effect
sizes were small in this study and caution is therefore advised in the
interpretation of the results pending future studies in independent
cohorts.
Data from this large cohort of older adults indicates links
between inflammatory activity and biological aging. In particular,
the present data indicate that the cumulative load of high IL-6 and
high TNF-a is accompanied by increased risk for short LTL. The
present data also replicate a previous finding of no association
between CRP and LTL in older adults, and suggest that systemic
inflammatory cytokines may have more relevance to leukocyte
telomere shortening than the more commonly used inflammatory
marker CRP. In sum, older adults with high levels of inflammatory
activity may be at increased risk for accelerated leukocyte telomere
shortening, and those with short LTL may have increased risk for
diseases with an inflammatory etiology.
Methods
Study Population
Study participants for this investigation included 1,962 well-
functioning men and women aged 70–79 years who participated
in Health ABC. Participants were identified from a random
sample of white Medicare beneficiaries and all age-eligible black
community residents in designated ZIP code areas surrounding
Pittsburgh and Memphis. To be eligible for participation in Health
ABC, participants had to report no difficulty in walking one-
quarter mile (0.5 km) or climbing 10 stairs without resting.
Exclusion criteria included reported difficulty performing basic
activities of daily living, obvious cognitive impairment, inability to
communicate with the interviewer, intention of moving within 3
years, or participation in a trial involving a lifestyle intervention.
Additionally, of the 3.075 participants who took part in Health
ABC, our sample of 1,962 includes only participants who had
complete data on LTL, inflammatory markers and all covariates
included in our analysis. Our sample was not significantly different
from excluded participants with missing data on age or site, but
they were less likely to be female (50.1% of subsample versus 54%
of non-sample, p=.04) and less likely to be Black (40% of
subsample versus 44.7% of non-sample, p=.01). All participants
gave written informed consent. The Institutional Review Boards at
the University of Pittsburgh, the University of Tennessee and the
University of California, San Francisco approved the protocol.
Baseline data were collected from 1997 to 1998.
LTL Measurement
Quantitative polymerase chain reaction (Q-PCR) was used to
measure LTL in the genomic DNA of peripheral leukocytes by
determining the ratio of telomere repeat copy number to single-
copy gene copy number (T/S ratio) in study samples relative to a
reference sample [47,49]. The Q-PCR assay was conducted on
three separate DNA samples per participant, and average LTL
was calculated as the mean value of these triplicates. Each T/S
value was later converted to number of base pairs (bp) by
multiplying the T/S value by the known LTL of the reference
DNA, which is a pooled sample of DNAs from several normal
Utah whites aged 65 years and older. The slope of the linear
regression line through a plot of T/S ratio (the x axis) versus mean
TRF length (the y axis) is the number of base pairs of telomeric
DNA corresponding to a single T/S unit. All samples were
measured in triplicate and the mean value of the triplicates was
used in analyses. The coefficient of variation for this assay is 4%
and results obtained with the Q-PCR method are strongly
associated with the traditional terminal restriction fragment length
index of LTL obtained by Southern blot technique [47]. DNA was
available for 2,880 of the 3,075 individuals who participated in
Health ABC, and LTL was successfully measured in 2,721 cases.
Inflammatory Markers
Blood samples for inflammatory markers were obtained in the
morning (median time was 9:19 AM; interquartile range was from
8:49 AM to 9:52 AM). IL-6 and CRP levels were measured in
serum and TNF-a levels were measured in plasma. Tubes for IL-6
and CRP were serum separator tubes containing no anticoagulant.
Tubes for TNF-a were citrated tubes containing 0.5 mL of 3.8%
sodium citrate. After processing, the specimens were aliquoted into
cryovials, frozen at 270uC, and shipped to the Core Laboratory at
the University of Vermont. Serum IL-6 levels and plasma TNF-a
levels were measured in duplicate by enzyme-linked immunosor-
bent assay (ELISA) kits from R&D Systems (Minneapolis, MN).
The detectable limit for IL-6 (by HS600 Quantikine kit) was
.10 pg/mL, and for TNF-a (by HSTA50 kit) was .18 pg/mL.
Plasma levels of CRP were also measured in duplicate by ELISA
based on purified protein and polyclonal anti-CRP antibodies
(Calbiochem, San Diego, CA). The CRP assay was standardized
according to the World Health Organization First International
Reference Standard, with a sensitivity of 0.08 mg/mL. Measures of
IL-6, TNF-a and CRP were missing for 162, 203, and 38
participants respectively. Intra and inter-assay coefficients of
variation for inflammatory markers were respectively: 10% and
15% for IL-6; 16% and 15% for TNF-a; and 8% and 5% for
CRP.
Covariates
Covariates were selected a priori based on previous research
and included characteristics associated with inflammatory markers
and LTL in previous research. Such a priori selection of covariates
has been validated for logistic regression procedures [50,51]. The
telomere batch number corresponds to a particular run of the Q-
PCR assay used to measure LTL. Because there is some variability
between assays, we controlled for telomere batch in all LTL
analyses, constructing a dummy variable for each batch to enter
into regression models. Sociodemographic covariates included
study site, age, gender, and race, as well as education (less than
high school; high school; more than high school) and income
(,$10 k; $10–25 k; $25–50 k; .$50 k). BMI was calculated as
weight in kilograms divided by height in meters squared.
Behavioral factors including smoking status (current, former,
never), average alcohol use during the past year (0, ,1, 1–7 or .7
drinks/week), exercise (total kilocalories burned per week) and
hours of sleep per night on average were assessed in the baseline
interview. Participants were asked whether they had experienced
symptoms of respiratory infections within the last 2 weeks. The
baseline presence of chronic illnesses including lung disease, heart
disease (including myocardial infarction, angina pectoris, and
congestive heart failure), stroke, diabetes mellitus, broken hip, and
arthritis was adjudicated using standardized algorithms consider-
ing various sources of information: self-report of a medical
diagnosis, medication use, and results of screening tests from a
clinical examination where appropriate. All medications regularly
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the Iowa Drug Information System (IDIS) code [52]. Using this
drug inventory, the daily use of antiinflammatory drugs (IDIS
codes 2808 or 5208) and statins (IDIS code 2406) was assessed.
Our primary models were run with three different sets of
covariates. First, adjusting only for telomere batch; second,
adjusting for telomere batch, as well as potential confounds
including study site, age, gender and race; and third, adjusting for
telomere batch, as well as potential confounds and other potential
covariates including study site, age, gender, race, income,
education, BMI, smoking status, alcohol use, exercise, sleep,
chronic disease, recent respiratory illness, and the use of anti-
inflammatory drugs or statins.
Statistical Analysis
Logistic regression and analysis of covariance were used to test
our primary hypothesis that high levels of inflammatory activity
would be associated with increased odds for short LTL, as indexed
by the odds of having LTL in the bottom tertile in the sample and
by LTL in base pairs, respectively. For the purpose of these
analyses, participants with values in the upper tertile of the sample
were classified as ‘‘high’’ for inflammatory markers and those with
values in the lower tertile of the sample were classified as ‘‘short’’
for LTL. We also examined if having CRP levels above the clinical
cutoff of .3 mg/L was associated with increased odds for short
LTL.
Logistic regression analyses were used to examine if participants
with high levels of IL-6, TNF-a and CRP alone or in combination
would be more likely than participants with lower levels of these
inflammatory markers to have short LTL. In our first set of
analyses, groups were not mutually exclusive, such that the same
individual could be represented in multiple groups if they had high
levels of IL-6, TNF-a or CRP. Based on the results of these
analyses, we excluded CRP from our model and conducted follow-
up analyses to examine if the odds for short LTL in participants
with high levels of both IL-6 and TNF-a was significantly higher
than that of participants with high levels of only IL-6, high levels of
only TNF-a, or high levels of neither IL-6 nor TNF-a. Thus, this
second group of logistic regression analyses were conducted on
mutually exclusive groups. All models were run with the three
different sets of covariates as described in the covariates section.
Analysis of covariance was used to compare mean differences in
base pairs of telomeres between those with and without high levels
of inflammatory markers.
In order to compare characteristics of the sample by telomere
length tertile we performed analysis of variance and Kruskal-
Wallis rank tests for continuous variables, and chi-squared tests for
categorical variables. In order to analyze differences in LTL and
cytokines by gender, linear regressions were used. Due to
unacceptable levels of skewness, the variables IL-6, TNF-a and
CRP were log-transformed when used in correlations and linear
regressions. All analyses were performed using Stata version 9.2
and SPSS version 18.0.
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